MedTrace Logo

Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

NCT00430508 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 972

Last updated 2019-01-09

Study results available
· View outcomes & findings →

Summary

The study will evaluate the blood pressure lowering effects of two different dosages of the combination of olmesartan and hydrochlorothiazide in patients with moderate or severe high blood pressure.

Conditions

  • Essential Hypertension

Interventions

DRUG

olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo

olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 week

DRUG

olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets

olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks

DRUG

olmesartan medoxomil/hydrochlorothiazide tablets

olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks

DRUG

olmesartan medoxomil/hydrochlorothiazide tablets

olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks

Sponsors & Collaborators

  • Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

    collaborator INDUSTRY

  • Daiichi Sankyo

    lead INDUSTRY

Principal Investigators

  • Professor Lars Christian Rump, M.D. · University of Ruhr-Bochum

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2008-03-31
Completion
2008-05-31

Countries

  • Bulgaria
  • Czechia
  • France
  • Germany
  • Poland
  • Spain
  • Ukraine

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00430508 on ClinicalTrials.gov